Gilead Reports Phase 2 Data for Pralsetinib in Meningioma

Gilead today announced Phase 2 results for Pralsetinib in patients with Meningioma. The study demonstrated that Pralsetinib reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Meningioma and support the continued development of Pralsetinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Pralsetinib was consistent with previous observations, with no new safety signals identified.